Publications
5491 Results
- Journal / Conference
- ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826
- Journal / Conference
- Clinical Cancer Research Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. Online ahead of print
- Year
- 2023
- Research Committee(s)
- Lung
- PMID
- PMID37903180
- Study Number(s)
- LUNGMAP
Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships
- Journal / Conference
- ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
- Year
- 2023
- Research Committee(s)
- Lymphoma
- Study Number(s)
- CTSU/A051301
Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201
- Journal / Conference
- ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral
- Year
- 2023
- Research Committee(s)
- Leukemia
Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome
- Journal / Conference
- ASH Annual Meeting (Dec9-12,2023, San Diego, CA), poster
- Year
- 2023
- Research Committee(s)
- Leukemia
- Study Number(s)
- CTSU/E1910
Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial
- Journal / Conference
- Clin Cancer Res 14;29(8):1477-1483
- Year
- 2023
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID36853016
- PMC
- PMC10102836
- Study Number(s)
- CTSU/EAY131
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
- Journal / Conference
- Society of Surgical Oncology (March 22-25, 2023, Boston, MA), oral plenary
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
Surgical outcomes of SWOG S1801: Neoadjuvant versus adjuvant pembrolizumab for resectable stage III-IV melanoma
- Journal / Conference
- Society of Surgical Oncology (March 22-25, 2023, Boston, MA), oral
- Year
- 2023
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
Neoadjuvant Pembrolizumab in Stage II-III Desmoplastic Melanoma (SWOG S1512): Surgical Considerations
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery
Quality Metrics in an NCTN Network Group
- Journal / Conference
- Society for Clinical Trials (May 21-24, 2023, Baltimore, MD), poster
- Year
- 2023
- Research Committee(s)
- Cancer Care Delivery